The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥522.68Fair value¥3,234.91Bull¥5,217.63
FairClose
52-week traded range
52W low ¥1,689.0052W high ¥2,674.50
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
ONO PHARMACEUTICAL CO.,LTD. closed at ¥2,320.00, 28.3% below the consensus fair value of ¥3,234.91 drawn from 9 valuation models.
Financial DNA score 61/100 — Good. P/E of 15.6x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥5,217.63
+124.9%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
¥2,451.26
+5.7%
√(22.5 × EPS × BVPS)
EPS=148.49, BVPS=1798.45
P/E Fair Value
¥2,969.80
+28.0%
EPS × 20x (sector P/E)
EPS=148.49, Sector P/E=20x
Peter Lynch (PEG)
¥522.68
-77.5%
EPS × Growth% (PEG = 1 is fair)
EPS=148.49, g=3.5%
EV/EBITDA
¥2,591.78
+11.7%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=129.99B
Dividend Discount (DDM)
¥1,020.51
-56.0%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=80.04, r=10%, g=2%
Book Value (P/B)
¥1,413.07
-39.1%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=1798.45, ROE=8.5%, g=3%, r=10%
Reverse DCF
¥2,320.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 3.8% | Historical: -3.5%
Margin of Safety
¥2,659.67
+14.6%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=3546.23, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.